Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04427384 · ClinicalTrials.gov registry record
Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)
A clinical trial of Brain Tumor and Brain Tumor, Recurrent, sponsored by GT Medical Technologies.
- Recruiting
- Registry status
- 600
- Enrollment target
- 20
- Study locations
NCT04427384: Recruiting study of Brain Tumor and Brain Tumor, Recurrent, sponsored by GT Medical Technologies.
NCT04427384 is a study of Brain Tumor and Brain Tumor, Recurrent that is actively recruiting participants, run by GT Medical Technologies. The registered enrollment target is 600 participants, above the 273-participant average among 69 other Brain Tumor trials with a reported enrollment target (120% higher). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04427384, a study of Brain Tumor and Brain Tumor, Recurrent, is actively recruiting participants, sponsored by GT Medical Technologies.
- RECRUITING
- Registry status
- 600 participants
- Enrollment target
- 20
- Study locations
Study Summary
The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
Primary Outcome
No contrast enhancement in the area of the surgical bed
Conditions Studied
Interventions
- DEVICE GammaTile
Study Locations (20)
Florida
- BayCare Health - Clearwater
- Ascension St. Vincent's - Jacksonville
- Miami Cancer Institute, Baptist Health South Florida - Miami
- Advent Health Orlando - Orlando
- Orlando Health - Orlando
- Florida Health Sciences Center, Inc. d/b/a Tampa General Hospital - Tampa
- Cleveland Clinic Florida- Weston - Weston
California
- Eden Medical Center - Castro Valley
- UCSD Moores Cancer Center - La Jolla
- MemorialCare Health System - Laguna Hills
- Desert Regional Medical Center - Palm Springs
- California Pacific Medical Center, Sutter health - San Francisco
Colorado
- Centura - Denver
- Colorado Brain & Spine Institute: Swedish Campus - Englewood
Georgia
- Piedmont Healthcare - Atlanta
- Winship Cancer Institute of Emory University - Atlanta
Arizona
- HonorHeath Scottsdale Osborn Medical Center - Phoenix
Arkansas
- University of Arkansas Medical Center - Little Rock
Idaho
- St. Alphonsus Regional Medical Center - Boise
Indiana
- Goodman Campbell Brain and Spine - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2020-09-11 |
| Est. Completion | 2028-12-31 |
What NCT04427384 shows while recruiting
NCT04427384 is an observational study that tracks outcomes without assigning an intervention. The registered 600 participants enrollment target is mid-sized for trials with a published cap, above the 273-participant average among 69 other Brain Tumor trials with a reported enrollment target (120% higher).
The record links to 6 conditions, with Brain Tumor appearing as the primary indexed condition, and to 1 intervention - of which GammaTile is the first listed.
NCT04427384 names 20 study sites across 8 states, led by Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04427384 about?
NCT04427384 is a clinical study titled "Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)". The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.
What is the current status of trial NCT04427384?
This trial is currently recruiting. The enrollment target is 600 participants. The study started on 2020-09-11. Estimated completion is 2028-12-31.
What conditions does trial NCT04427384 study?
This clinical trial studies the following conditions: Brain Tumor, Brain Tumor, Recurrent, Brain Tumor, Primary, Brain Tumor - Metastatic, Brain Tumor, Adult: Glioblastoma.
What interventions are being tested in trial NCT04427384?
The interventions under investigation include: GammaTile (DEVICE).
Who is sponsoring clinical trial NCT04427384?
This trial is sponsored by GT Medical Technologies, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04427384 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04427384's enrollment target sits among peer trials
600 6th of 69 higher than 64 of 69 other Brain Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain
RECRUITING
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
LITT Followed by Hypofractionated RT for Newly Diagnosed Gliomas (GCC 20138)
RECRUITING · NA
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004317 · 600 participants · Phase 4
Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis
- NCT00209235 · 600 participants · NA
Albright Hereditary Osteodystrophy: Natural History, Growth, and Cognitive/Behavioral Assessments
- NCT01473784 · 600 participants · NA
Transoral Robotic Surgery in Treating Patients With Benign or Malignant Tumors of the Head and Neck
- NCT01866371 · 600 participants
High Resolution Retinal Imaging
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI